{"id":40695,"date":"2025-09-04T15:20:51","date_gmt":"2025-09-04T07:20:51","guid":{"rendered":"https:\/\/flcube.com\/?p=40695"},"modified":"2025-09-04T15:20:52","modified_gmt":"2025-09-04T07:20:52","slug":"argo-biopharma-novartis-expand-sirna-collaboration-for-cardiovascular-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40695","title":{"rendered":"Argo\u202fBiopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs"},"content":{"rendered":"\n

Argo Biopharma<\/strong>, a Shanghai\u2011based siRNA drug developer, announced a new strategic cooperation agreement with Novartis<\/strong> (NYSE: NVS<\/a>). The deal deepens an already\u2011existing collaboration and opens the door to multiple cardiovascular products.<\/p>\n\n\n\n

Key Deal Elements<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Option Rights<\/strong><\/td>Novartis receives out\u2011of\u2011China option rights for two early\u2011stage molecules targeting severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.<\/td><\/tr>
First\u2011Negotiation Right<\/strong><\/td>Novartis holds the right of first negotiation for BW\u201100112 (ANGPTL3), a Phase\u202f2 candidate in the U.S. and China.<\/td><\/tr>
Exclusive License<\/strong><\/td>For a pre\u2011clinical siRNA candidate, Novartis obtains an exclusive out\u2011of\u2011China license and a reciprocal profit\u2011and\u2011loss sharing option in the U.S. and China.<\/td><\/tr>
Clinical Milestones<\/strong><\/td>BW\u201100112 will proceed to combination\u2011therapy trials under Argo\u2019s leadership; the pre\u2011clinical candidate is slated for Phase\u202fI in 2026.<\/td><\/tr>
Financial Terms<\/strong><\/td>Argo receives a $160\u202fM upfront payment, with potential milestone and option payments totalling up to $5.2\u202fB and tiered royalties on commercial sales.<\/td><\/tr>
Future Equity<\/strong><\/td>Novartis has signaled a preliminary interest in Argo\u2019s next equity round, subject to due diligence and final negotiations.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n